The portfolio maintains a sizable cost advantage over competitors, priced within the cheapest fee quintile among peers.
ALPS Medical Breakthroughs ETF SBIO
- NAV / 1-Day Return 34.59 / +0.40 %
- Total Assets 110.7 Mil
-
Adj. Expense Ratio
- Expense Ratio 0.500%
- Distribution Fee Level —
- Share Class Type —
- Category Health
- Investment Style Small Growth
- Min. Initial Investment —
- Status Open
- TTM Yield 0.22%
- Turnover 81%
USD | NAV as of May 08, 2024 | 1-Day Return as of May 08, 2024, 12:24 AM GMT+0
Morningstar’s Analysis SBIO
Will SBIO outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 32.7
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Viking Therapeutics Inc | 5.19 | 5.7 Mil | Healthcare |
Cerevel Therapeutics Holdings Inc Ordinary Shares | 4.88 | 5.4 Mil | Healthcare |
Vaxcyte Inc Ordinary Shares | 4.54 | 5.0 Mil | Healthcare |
Revolution Medicines Inc Ordinary Shares | 4.07 | 4.5 Mil | Healthcare |
Alpine Immune Sciences Inc | 2.68 | 3.0 Mil | Healthcare |
Alkermes PLC | 2.54 | 2.8 Mil | Healthcare |
Crinetics Pharmaceuticals Inc | 2.29 | 2.5 Mil | Healthcare |
Axsome Therapeutics Inc | 2.28 | 2.5 Mil | Healthcare |
SpringWorks Therapeutics Inc Ordinary Shares | 2.16 | 2.4 Mil | Healthcare |
Xenon Pharmaceuticals Inc | 2.06 | 2.3 Mil | Healthcare |